[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-cicatricial-pemphigoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-cicatricial-pemphigoid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100587291","phase-1-subconjunctival-humira-for-boston-keratoprosthesis-100587291",false,"NCT06926478","Subconjunctival Humira for Boston Keratoprosthesis","Clinical Trial to Evaluate Short-term Safety of Subconjunctival Adalimumab in Combination With Type 1 Boston Keratoprosthesis Implantation","Inclusion Criteria:\n\n* Age 18 years or older\n* Individuals eligible for keratoprosthesis surgery, as determined by standard-of-care eligibility criteria\n* Patients with poor prognosis for corneal transplantation, severe corneal opacity and\u002For vascularization\n* Patients with vision worse than 20\u002F200 in the eligible eye, and contralateral eye with vision less than 20\u002F40\n* Patients with intact nasal light projection\n* Willing and able to comply with study plan for the full duration of the study\n* Willing and able to sign a written informed consent\n\nExclusion Criteria:\n\n* Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-# release assay \\[IGRA\\] test, such as Quantiferon-gold)\n* Untreated active hepatitis B or C infection.\n* Ocular or periocular malignancy and\u002For infection\n* Inability to wear contact lens\n* Pregnancy (positive pregnancy test) or lactating\n* Participation in another interventional study at the time of screening\n* Any of the following baseline lab values\n\n  1. White blood count \\\u003C3500 cells per microliter\n  2. Platelets \\\u003C100,000 per microliter\n  3. Hematocrit \\\u003C30%\n  4. AST or ALT \\>1.5X upper limit normal value\n* Multiple sclerosis or other demyelinating disease\n* Severe uncontrolled infection\n* Moderate to severe heart failure (NYHA class III\u002FIV)\n* Active malignancy\n* History of adalimumab intolerance\n* Pregnancy or lactation\n* Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.\n* As judged by the investigator any patients that are questionable for their suitability in the study","ALL","18 Years",{"count":19,"type":20},8,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.",[26,27,28,29],"Penetrating Keratoplasty","Multiple Graft Failure","Ocular Cicatricial Pemphigoid","Stevens-Johnson Syndrome",[31,32,33,34],"Kpro","Boston Kpro","Keratoprosthesis","Type-1 Boston Kpro","NOT_YET_RECRUITING","2026-03-23",{"date":38,"type":39},"2026-03-27","ACTUAL",{"date":41,"type":20},"2026-06-01",{"date":43,"type":20},"2028-06-01",{"name":45,"class":46},"Massachusetts Eye and Ear Infirmary","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100220642","clinical-trial-on-the-effect-of-autologous-oral-mucosal-epithelial-sheet-transplantation-100220642","NCT02149732","Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation","An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients","Inclusion Criteria:\n\n1. patient with eye which has limbal stem cell deficiency and conjunctivalization of cornea\n2. patient who shows no improvement after limbal tissue or amniotic membrane transplantation, or who has difficulty in receiving long-term immunosuppressive treatment\n3. patient who agree this clinical trial\n4. patient with the eyes in which best corrected visual acuity is less than counting finger\n5. patient who is older than sixteen year old\n\nExclusion Criteria:\n\n1. patient who has relevant corneal transparency\n2. patient who is on the pregnancy or has a plan of pregnancy within 1 year\n3. patient who has corneal infection\n4. patient who has diagnosis of HBV, HCV, HIV, syphilis\n5. patinet who has past medial history of antinal, myocardial infarction, heart failure, arrhythmia, brain stroke, cerebrovascular disease\n6. patient who has malignancy\n7. patient who shows hypersensitivity to bovine protein.","16 Years","EXPANDED_ACCESS","To investigate the effect of ocular surface reconstruction and assess the safety in cultivated oral mucosal epithelial cell sheet transplantation (COMET) regarding patients with cicatricial change of ocular surface.",[59,60,28,61],"Limbal Stem Cell Deficiency","Stevens-johnson Syndrome","Chemical Burn",[63,64,65],"Limbal stem cell deficiency","Cultivated oral mucosal cell sheet transplantation","Ocular surface reconstruction","AVAILABLE","2016-04-18",{"date":69,"type":20},"2016-04-20",{"date":71,"type":4},"2014-05",{"date":73,"type":20},"2016-12",{"name":75,"class":46},"Seoul National University Hospital"]